{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:35:23Z","timestamp":1782826523102,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T00:00:00Z","timestamp":1562803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Health","award":["NIH P30 DK072482 and R35 HL135816"],"award-info":[{"award-number":["NIH P30 DK072482 and R35 HL135816"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12876-019-1044-7","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T15:02:49Z","timestamp":1562857369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"J. Dixon","family":"Johns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,11]]},"reference":[{"issue":"2","key":"1044_CR1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/00004836-199909000-00007","volume":"29","author":"S Nousia-Arvanitakis","year":"1999","unstructured":"Nousia-Arvanitakis S. Cystic fibrosis and the pancreas: recent scientific advances. J Clin Gastroenterol. 1999;29(2):138\u201342.","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"1044_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/MEG.0b013e3282f36d04","volume":"20","author":"A Augarten","year":"2008","unstructured":"Augarten A, et al. The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype. Eur J Gastroenterol Hepatol. 2008;20(3):164\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"1044_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1053\/j.gastro.2010.09.046","volume":"140","author":"CY Ooi","year":"2011","unstructured":"Ooi CY, et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology. 2011;140(1):153\u201361.","journal-title":"Gastroenterology"},{"issue":"10","key":"1044_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJM199809033391001","volume":"339","author":"N Sharer","year":"1998","unstructured":"Sharer N, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med. 1998;339(10):645\u201352.","journal-title":"N Engl J Med"},{"issue":"8","key":"1044_CR5","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/gut.52.8.1159","volume":"52","author":"N Ahmed","year":"2003","unstructured":"Ahmed N, et al. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut. 2003;52(8):1159\u201364.","journal-title":"Gut"},{"issue":"2","key":"1044_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1203\/00006450-199208000-00011","volume":"32","author":"RT Couper","year":"1992","unstructured":"Couper RT, et al. Decline of exocrine pancreatic function in cystic fibrosis patients with pancreatic sufficiency. Pediatr Res. 1992;32(2):179\u201382.","journal-title":"Pediatr Res"},{"issue":"1","key":"1044_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1373\/clinchem.2003.028068","volume":"50","author":"S Sebastian","year":"2004","unstructured":"Sebastian S, et al. Multicenter characterization and validation of the intron-8 poly(T) tract (IVS8-T) status in 25 Coriell cell repository cystic fibrosis reference cell lines for cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation assays. Clin Chem. 2004;50(1):251\u20134.","journal-title":"Clin Chem"},{"issue":"3","key":"1044_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/ng1193-274","volume":"5","author":"S Kiesewetter","year":"1993","unstructured":"Kiesewetter S, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet. 1993;5(3):274\u20138.","journal-title":"Nat Genet"},{"issue":"18","key":"1044_CR9","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMc1510466","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright CE, Elborn JS, Ramsey BW. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(18):1783\u20134.","journal-title":"N Engl J Med"},{"issue":"3","key":"1044_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/23808993.2016.1175299","volume":"1","author":"DM Cholon","year":"2016","unstructured":"Cholon DM, Esther CR Jr, Gentzsch M. Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation. Expert Rev Precis Med Drug Dev. 2016;1(3):235\u201343.","journal-title":"Expert Rev Precis Med Drug Dev"},{"issue":"3","key":"1044_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2017.10","volume":"8","author":"D Gelfond","year":"2017","unstructured":"Gelfond D, et al. Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation. Clin Transl Gastroenterol. 2017;8(3):e81.","journal-title":"Clin Transl Gastroenterol"},{"issue":"2","key":"1044_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","volume":"4","author":"JC Davies","year":"2016","unstructured":"Davies JC, et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med. 2016;4(2):107\u201315.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"1044_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","volume":"6","author":"M Rosenfeld","year":"2018","unstructured":"Rosenfeld M, et al. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med. 2018;6(7):545\u201353.","journal-title":"Lancet Respir Med"},{"issue":"21","key":"1044_CR14","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","volume":"377","author":"SM Rowe","year":"2017","unstructured":"Rowe SM, et al. Tezacaftor-Ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med. 2017;377(21):2024\u201335.","journal-title":"N Engl J Med"},{"issue":"3","key":"1044_CR15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/MPG.0000000000001788","volume":"66","author":"A Carrion","year":"2018","unstructured":"Carrion A, et al. Reduction of recurrence risk of pancreatitis in cystic fibrosis with Ivacaftor: case series. J Pediatr Gastroenterol Nutr. 2018;66(3):451\u20134.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"1044_CR16","doi-asserted-by":"publisher","first-page":"7234","DOI":"10.1038\/s41598-019-43652-2","volume":"9","author":"AR Habib","year":"2019","unstructured":"Habib AR, et al. A systematic review of the clinical efficacy and safety of CFTR modulators in cystic fibrosis. Sci Rep. 2019;9(1):7234.","journal-title":"Sci Rep"},{"issue":"6","key":"1044_CR17","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1016\/S2213-2600(16)30047-9","volume":"4","author":"GM Solomon","year":"2016","unstructured":"Solomon GM, et al. Pilot evaluation of ivacaftor for chronic bronchitis. Lancet Respir Med. 2016;4(6):e32\u20133.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"1044_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1165\/rcmb.2013-0228OC","volume":"50","author":"JA Lambert","year":"2014","unstructured":"Lambert JA, et al. Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis. Am J Respir Cell Mol Biol. 2014;50(3):549\u201358.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1044_CR19","unstructured":"Ivacaftor (Kalydeco) for cystic fibrosis. Med Lett Drugs Ther, 2012. 54(1388): p. 29\u201330."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1044-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-019-1044-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1044-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T23:13:44Z","timestamp":1594336424000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-019-1044-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,11]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1044"],"URL":"https:\/\/doi.org\/10.1186\/s12876-019-1044-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,11]]},"assertion":[{"value":"20 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SMR receives grant funding and consulting income for the design and conduct of clinical trials related to cystic fibrosis and other related conditions from Vertex Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}